Study on didanosine concentrations in cerebrospinal fluid
- 24 Downloads
It has been hypothesized that didanosine has a low efficacy in the prevention and treatment of patients with the dementia complex of acquired immunodeficiency syndrome (AIDS) because “...the drug has not been detected in the cerebrospinal fluid”. We investigated didanosine concentrations in cerebrospinal fluid (CSF) and plasma of four patients with AIDS who were using didanosine chronically. Didanosine levels, 4 h after the last drug administration, averaged 0.16 (±0.03) μmol/l in CSF and 0.70 (±0.27) μmol/l in plasma. When compared with historical data from patients using zidovudine, didanosine concentrations in CSF appeared to be approximately half (on a molar base) those of zidovudine concentrations in the CSF. Whether this difference in CSF levels is the explanation for the presumed lower efficacy of didanosine in the prevention and treatment of AIDS dementia complex remains to be proven. However, it is clear from this study, in contrast with earlier suggestions, that didanosine is able to pass the blood-CSF barrier in human immunodeficiency virus-infected individuals.
KeywordsAcquired immunodeficiency syndrome AIDS dementia complex Blood-brain barrier Cerebrospinal fluid Didanosine Pharmacokinetics
Unable to display preview. Download preview PDF.
- 6.Gray F, Geny C, Dournon C, Fenelon G, Lionnet F, Gherardi R. Neuropathological evidence that zidovudine reduces incidence of HIV infection of brain. Lancet 1991;337:852–3.Google Scholar
- 13.Portegies P, Enting RH, De Jong MD, Danner SA, Reiss P, Goudsmit J, et al. AIDS dementia complex and didanosine. Lancet 1994;344:759–60.Google Scholar
- 15.Beijnen JH, Meenhorst PL, Rosing H, Van Gijn R, Los G, Underberg WJM. Analysis of 2′,3′-dideoxyinosine (ddl) in plasma by isocratic high-performance liquid chromatography with ultraviolet detection. J Drug Dev 1990;3:127–33.Google Scholar
- 18.Balis FM, Pizzo PA, Butler KM, Hawkins ME, Brouwers P, Husson RN, et al. Clinical pharmacology of 2′,3′-dideoxyinosine in human immunodeficiency virus-infected children. J Inf Dis 1992;165(1):99–104.Google Scholar